Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis
Received 9 May 2016
Accepted for publication 25 July 2016
Published 21 September 2016 Volume 2016:9 Pages 5771—5779
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Jian Xiao, Yong Zou, Xiaoxiao Lu, Bin Xie, Qiao Yu, Baimei He, Bixiu He, Qiong Chen
Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, People’s Republic of China
Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.
Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.
Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.
Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.
Keywords: prognosis, microRNA-133a, solid cancers, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]